What is the purpose of this study?
This study will test the experimental drug Lenacapavir (LEN) for the prevention of HIV infection, also known as Pre-Exposure Prophylaxis (PrEP). This study will also compare the effectiveness of LEN to Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF; Truvada), which has already been approved in several countries for use as PrEP.
INTERESTED IN LEARNING MORE ABOUT TWICE A YEAR MEDICATION FOR PrEP?
You may be eligible for a study testing an investigational injectable PrEP medication given twice a year if:
You’re over 18 years old
You haven’t been tested for HIV in the last 3 months
You’re having anal sex with men or transwomen partners and don’t always use condoms
CONTACT US: 323-461-3106